MSHLTrastuzumab deruxtecan Powder For Concentrate For Solution For Infusion 100 mg
1) Treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.
2) Treatment of HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior regimens, including a trastuzumab-based regimen.
3) Treatment of patients with HER2-low unresectable and/or metastatic breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with HR-positive breast cancer should have received at least one and be no longer considered eligible for endocrine therapy.